Concepts (252)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Mammaplasty | 20 | 2023 | 109 | 8.670 |
Why?
|
| Adipose Tissue | 21 | 2024 | 259 | 7.640 |
Why?
|
| Breast Neoplasms | 25 | 2024 | 3011 | 3.300 |
Why?
|
| Transplantation, Autologous | 16 | 2022 | 344 | 2.640 |
Why?
|
| Mastectomy, Segmental | 5 | 2023 | 101 | 1.960 |
Why?
|
| Breast Implants | 5 | 2020 | 25 | 1.890 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 5 | 2013 | 61 | 1.540 |
Why?
|
| Adipocytes | 3 | 2022 | 162 | 1.530 |
Why?
|
| Venous Thrombosis | 3 | 2018 | 253 | 1.500 |
Why?
|
| Lymphedema | 2 | 2022 | 77 | 1.430 |
Why?
|
| Mastectomy | 11 | 2023 | 245 | 1.350 |
Why?
|
| Breast | 9 | 2022 | 292 | 1.340 |
Why?
|
| Lymphoma, Large-Cell, Anaplastic | 4 | 2020 | 9 | 1.310 |
Why?
|
| Anastomosis, Surgical | 3 | 2018 | 273 | 1.270 |
Why?
|
| Free Tissue Flaps | 4 | 2021 | 49 | 0.940 |
Why?
|
| Tissue and Organ Harvesting | 3 | 2021 | 78 | 0.930 |
Why?
|
| Tissue Scaffolds | 3 | 2014 | 112 | 0.890 |
Why?
|
| Humans | 61 | 2024 | 89357 | 0.870 |
Why?
|
| Fat Necrosis | 1 | 2022 | 6 | 0.840 |
Why?
|
| Face | 1 | 2022 | 116 | 0.800 |
Why?
|
| Postoperative Complications | 7 | 2022 | 2284 | 0.800 |
Why?
|
| Microsurgery | 4 | 2022 | 88 | 0.800 |
Why?
|
| Tissue Engineering | 5 | 2021 | 185 | 0.760 |
Why?
|
| Wound Healing | 3 | 2013 | 359 | 0.730 |
Why?
|
| Ki-1 Antigen | 1 | 2020 | 19 | 0.700 |
Why?
|
| Female | 37 | 2024 | 46202 | 0.690 |
Why?
|
| Lipectomy | 1 | 2019 | 9 | 0.660 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2020 | 374 | 0.650 |
Why?
|
| Patient Education as Topic | 1 | 2021 | 360 | 0.630 |
Why?
|
| Acellular Dermis | 1 | 2018 | 5 | 0.630 |
Why?
|
| Tissue Expansion | 1 | 2018 | 19 | 0.620 |
Why?
|
| Breast Implantation | 1 | 2018 | 13 | 0.620 |
Why?
|
| Mass Screening | 1 | 2022 | 636 | 0.590 |
Why?
|
| Middle Aged | 19 | 2024 | 25974 | 0.570 |
Why?
|
| Macrophages | 4 | 2013 | 571 | 0.570 |
Why?
|
| Abdominal Fat | 2 | 2013 | 13 | 0.560 |
Why?
|
| Immunophenotyping | 3 | 2013 | 217 | 0.560 |
Why?
|
| Hydrogel, Polyethylene Glycol Dimethacrylate | 2 | 2013 | 31 | 0.490 |
Why?
|
| Bone Marrow Cells | 2 | 2013 | 262 | 0.490 |
Why?
|
| Hyaluronic Acid | 2 | 2013 | 49 | 0.490 |
Why?
|
| Prospective Studies | 8 | 2022 | 4289 | 0.470 |
Why?
|
| Immunomodulation | 1 | 2014 | 58 | 0.470 |
Why?
|
| Adult | 19 | 2024 | 26607 | 0.450 |
Why?
|
| Skin | 3 | 2019 | 582 | 0.440 |
Why?
|
| Biocompatible Materials | 1 | 2014 | 198 | 0.430 |
Why?
|
| Retrospective Studies | 14 | 2022 | 9057 | 0.420 |
Why?
|
| Perforator Flap | 2 | 2022 | 12 | 0.410 |
Why?
|
| Autografts | 3 | 2021 | 28 | 0.400 |
Why?
|
| Cell Lineage | 1 | 2013 | 291 | 0.400 |
Why?
|
| Aged | 14 | 2021 | 19165 | 0.360 |
Why?
|
| Tracheal Diseases | 1 | 2010 | 14 | 0.360 |
Why?
|
| Laryngeal Diseases | 1 | 2010 | 21 | 0.360 |
Why?
|
| Filtration | 2 | 2021 | 25 | 0.360 |
Why?
|
| Time and Motion Studies | 2 | 2021 | 21 | 0.360 |
Why?
|
| Vocal Cords | 1 | 2010 | 28 | 0.350 |
Why?
|
| Seroma | 2 | 2020 | 7 | 0.330 |
Why?
|
| Propensity Score | 2 | 2021 | 147 | 0.330 |
Why?
|
| Follow-Up Studies | 9 | 2020 | 3666 | 0.320 |
Why?
|
| Skin Diseases | 1 | 2010 | 173 | 0.310 |
Why?
|
| Surgery, Plastic | 2 | 2021 | 42 | 0.280 |
Why?
|
| Fibroblasts | 1 | 2010 | 755 | 0.280 |
Why?
|
| Cell Survival | 2 | 2024 | 983 | 0.280 |
Why?
|
| Flow Cytometry | 4 | 2013 | 691 | 0.280 |
Why?
|
| Wounds and Injuries | 1 | 2010 | 259 | 0.280 |
Why?
|
| Stem Cells | 2 | 2024 | 372 | 0.270 |
Why?
|
| Time Factors | 6 | 2020 | 5338 | 0.270 |
Why?
|
| Head and Neck Neoplasms | 3 | 2019 | 1063 | 0.260 |
Why?
|
| Neoplasms | 1 | 2021 | 3041 | 0.260 |
Why?
|
| Coculture Techniques | 4 | 2013 | 174 | 0.260 |
Why?
|
| Cells, Cultured | 6 | 2013 | 2884 | 0.250 |
Why?
|
| Patient Preference | 2 | 2023 | 111 | 0.240 |
Why?
|
| Axilla | 1 | 2024 | 104 | 0.230 |
Why?
|
| Young Adult | 6 | 2021 | 6312 | 0.220 |
Why?
|
| Cell Differentiation | 5 | 2013 | 1525 | 0.220 |
Why?
|
| Treatment Outcome | 5 | 2022 | 8241 | 0.210 |
Why?
|
| Lymph Node Excision | 1 | 2024 | 220 | 0.210 |
Why?
|
| Mammary Arteries | 1 | 2022 | 33 | 0.210 |
Why?
|
| Trauma Centers | 2 | 2015 | 146 | 0.210 |
Why?
|
| Shoulder | 1 | 2022 | 42 | 0.200 |
Why?
|
| Dietary Supplements | 1 | 2022 | 125 | 0.200 |
Why?
|
| Cytokines | 2 | 2024 | 803 | 0.200 |
Why?
|
| Myocutaneous Flap | 1 | 2021 | 5 | 0.200 |
Why?
|
| Arm | 1 | 2022 | 97 | 0.200 |
Why?
|
| Patient Satisfaction | 2 | 2022 | 461 | 0.200 |
Why?
|
| Community Participation | 1 | 2021 | 38 | 0.190 |
Why?
|
| Embolism, Fat | 1 | 2021 | 2 | 0.190 |
Why?
|
| Centrifugation | 1 | 2021 | 24 | 0.190 |
Why?
|
| Drainage | 1 | 2022 | 162 | 0.190 |
Why?
|
| Lymphangiogenesis | 1 | 2021 | 39 | 0.190 |
Why?
|
| Clothing | 1 | 2020 | 7 | 0.180 |
Why?
|
| Rectus Abdominis | 2 | 2010 | 40 | 0.180 |
Why?
|
| Cadaver | 2 | 2018 | 185 | 0.170 |
Why?
|
| Physicians, Women | 1 | 2020 | 56 | 0.170 |
Why?
|
| Aged, 80 and over | 6 | 2021 | 6811 | 0.170 |
Why?
|
| Nipples | 1 | 2019 | 37 | 0.170 |
Why?
|
| Organ Sparing Treatments | 1 | 2019 | 46 | 0.170 |
Why?
|
| Quality of Life | 3 | 2022 | 1668 | 0.170 |
Why?
|
| Skin Transplantation | 2 | 2010 | 184 | 0.160 |
Why?
|
| Time-to-Treatment | 1 | 2020 | 114 | 0.160 |
Why?
|
| Subcutaneous Fat | 1 | 2018 | 22 | 0.160 |
Why?
|
| Freeze Drying | 1 | 2018 | 15 | 0.160 |
Why?
|
| Surgical Wound Dehiscence | 1 | 2018 | 37 | 0.150 |
Why?
|
| Operating Rooms | 1 | 2019 | 129 | 0.150 |
Why?
|
| Surgical Flaps | 2 | 2010 | 249 | 0.150 |
Why?
|
| Endothelial Cells | 1 | 2021 | 460 | 0.150 |
Why?
|
| Graft Survival | 2 | 2021 | 900 | 0.150 |
Why?
|
| Education, Medical | 1 | 2020 | 243 | 0.150 |
Why?
|
| Microvessels | 1 | 2017 | 69 | 0.150 |
Why?
|
| Treatment Failure | 1 | 2018 | 287 | 0.150 |
Why?
|
| Lidocaine | 1 | 2017 | 65 | 0.140 |
Why?
|
| Epinephrine | 1 | 2017 | 88 | 0.140 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2021 | 533 | 0.140 |
Why?
|
| Suture Techniques | 1 | 2017 | 140 | 0.140 |
Why?
|
| Anesthetics, Local | 1 | 2017 | 76 | 0.140 |
Why?
|
| Surgeons | 1 | 2020 | 248 | 0.140 |
Why?
|
| Esthetics | 2 | 2020 | 45 | 0.140 |
Why?
|
| Pilot Projects | 1 | 2019 | 871 | 0.130 |
Why?
|
| Surgical Wound Infection | 1 | 2018 | 201 | 0.130 |
Why?
|
| Mammography | 1 | 2019 | 472 | 0.130 |
Why?
|
| Male | 9 | 2021 | 42411 | 0.130 |
Why?
|
| Patient Readmission | 1 | 2019 | 352 | 0.130 |
Why?
|
| Facial Injuries | 1 | 2015 | 19 | 0.130 |
Why?
|
| Students, Medical | 1 | 2020 | 419 | 0.130 |
Why?
|
| Quality Improvement | 1 | 2019 | 451 | 0.130 |
Why?
|
| Reproducibility of Results | 2 | 2020 | 2758 | 0.130 |
Why?
|
| Foreign-Body Reaction | 1 | 2014 | 11 | 0.120 |
Why?
|
| Pain, Postoperative | 1 | 2017 | 252 | 0.120 |
Why?
|
| Wounds, Nonpenetrating | 1 | 2015 | 113 | 0.110 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2021 | 1365 | 0.110 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2015 | 296 | 0.110 |
Why?
|
| Clinical Protocols | 1 | 2014 | 157 | 0.110 |
Why?
|
| Receptors, Fibroblast Growth Factor | 1 | 2013 | 16 | 0.110 |
Why?
|
| Gelatin | 1 | 2013 | 25 | 0.110 |
Why?
|
| Forkhead Transcription Factors | 1 | 2014 | 171 | 0.110 |
Why?
|
| Reoperation | 2 | 2019 | 599 | 0.110 |
Why?
|
| Swine, Miniature | 1 | 2013 | 50 | 0.110 |
Why?
|
| Cell Separation | 1 | 2013 | 198 | 0.110 |
Why?
|
| Internship and Residency | 2 | 2020 | 1045 | 0.110 |
Why?
|
| Sus scrofa | 1 | 2013 | 50 | 0.110 |
Why?
|
| Fibroblast Growth Factors | 1 | 2013 | 82 | 0.110 |
Why?
|
| Neoplastic Stem Cells | 1 | 2014 | 162 | 0.110 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2015 | 2661 | 0.110 |
Why?
|
| Adolescent | 3 | 2021 | 9263 | 0.110 |
Why?
|
| Device Removal | 2 | 2013 | 168 | 0.100 |
Why?
|
| Epidermis | 1 | 2013 | 102 | 0.100 |
Why?
|
| Cell Communication | 1 | 2013 | 199 | 0.100 |
Why?
|
| Surgicenters | 1 | 2011 | 5 | 0.100 |
Why?
|
| Mannose-Binding Lectins | 1 | 2011 | 6 | 0.100 |
Why?
|
| Lipopolysaccharide Receptors | 1 | 2011 | 23 | 0.100 |
Why?
|
| Antigens, CD | 1 | 2013 | 466 | 0.100 |
Why?
|
| HLA-DR Antigens | 1 | 2011 | 59 | 0.100 |
Why?
|
| Respiration, Artificial | 1 | 2014 | 352 | 0.100 |
Why?
|
| Swine | 1 | 2013 | 582 | 0.100 |
Why?
|
| Maxillofacial Injuries | 1 | 2011 | 4 | 0.100 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2013 | 887 | 0.100 |
Why?
|
| Receptors, IgG | 1 | 2011 | 53 | 0.090 |
Why?
|
| Skull Fractures | 1 | 2011 | 25 | 0.090 |
Why?
|
| Lectins, C-Type | 1 | 2011 | 86 | 0.090 |
Why?
|
| Interdisciplinary Communication | 1 | 2011 | 131 | 0.090 |
Why?
|
| Rejuvenation | 1 | 2010 | 20 | 0.090 |
Why?
|
| Polymerase Chain Reaction | 1 | 2013 | 922 | 0.090 |
Why?
|
| Regenerative Medicine | 1 | 2010 | 25 | 0.090 |
Why?
|
| Cooperative Behavior | 1 | 2011 | 179 | 0.090 |
Why?
|
| Transplantation, Homologous | 1 | 2013 | 996 | 0.090 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2010 | 61 | 0.090 |
Why?
|
| Monocytes | 1 | 2011 | 218 | 0.090 |
Why?
|
| Receptors, Cell Surface | 1 | 2011 | 289 | 0.090 |
Why?
|
| Adipogenesis | 1 | 2009 | 39 | 0.090 |
Why?
|
| MicroRNAs | 1 | 2014 | 551 | 0.080 |
Why?
|
| Patient Care Team | 1 | 2011 | 284 | 0.080 |
Why?
|
| Academic Medical Centers | 1 | 2011 | 385 | 0.080 |
Why?
|
| Monitoring, Physiologic | 1 | 2010 | 266 | 0.080 |
Why?
|
| Regeneration | 1 | 2010 | 150 | 0.080 |
Why?
|
| Cell Culture Techniques | 1 | 2009 | 192 | 0.080 |
Why?
|
| Islets of Langerhans | 1 | 2012 | 549 | 0.080 |
Why?
|
| Disease Models, Animal | 2 | 2013 | 2366 | 0.080 |
Why?
|
| In Vitro Techniques | 1 | 2010 | 996 | 0.080 |
Why?
|
| Cell Membrane | 1 | 2011 | 672 | 0.080 |
Why?
|
| Extracellular Matrix | 1 | 2009 | 245 | 0.080 |
Why?
|
| Interferon-gamma | 1 | 2010 | 451 | 0.080 |
Why?
|
| Gene Expression Regulation | 2 | 2013 | 1976 | 0.080 |
Why?
|
| Mutation | 1 | 2019 | 4143 | 0.070 |
Why?
|
| Glucose | 1 | 2010 | 630 | 0.070 |
Why?
|
| Phenotype | 1 | 2013 | 2440 | 0.070 |
Why?
|
| Biomarkers | 1 | 2013 | 1767 | 0.070 |
Why?
|
| Chronic Disease | 1 | 2010 | 950 | 0.070 |
Why?
|
| Prognosis | 3 | 2019 | 3783 | 0.070 |
Why?
|
| Animals | 3 | 2014 | 27371 | 0.060 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2024 | 72 | 0.060 |
Why?
|
| Ribs | 1 | 2022 | 46 | 0.050 |
Why?
|
| Delphi Technique | 1 | 2022 | 92 | 0.050 |
Why?
|
| Lymphatic Metastasis | 1 | 2024 | 502 | 0.050 |
Why?
|
| Disease-Free Survival | 2 | 2015 | 1214 | 0.050 |
Why?
|
| Buttocks | 1 | 2021 | 10 | 0.050 |
Why?
|
| Neoadjuvant Therapy | 1 | 2024 | 377 | 0.050 |
Why?
|
| Consensus | 1 | 2022 | 356 | 0.050 |
Why?
|
| Combined Modality Therapy | 1 | 2024 | 1719 | 0.040 |
Why?
|
| Lymph Nodes | 1 | 2024 | 548 | 0.040 |
Why?
|
| Survivorship | 1 | 2020 | 20 | 0.040 |
Why?
|
| Elasticity | 1 | 2019 | 96 | 0.040 |
Why?
|
| Needs Assessment | 1 | 2020 | 157 | 0.040 |
Why?
|
| Neoplasm Staging | 1 | 2024 | 2018 | 0.040 |
Why?
|
| Gene Expression | 2 | 2013 | 1310 | 0.040 |
Why?
|
| BRCA2 Protein | 1 | 2019 | 161 | 0.040 |
Why?
|
| Inpatients | 1 | 2021 | 310 | 0.040 |
Why?
|
| Single-Blind Method | 1 | 2018 | 150 | 0.040 |
Why?
|
| Cancer Survivors | 1 | 2020 | 95 | 0.040 |
Why?
|
| Cell Line, Tumor | 2 | 2014 | 2558 | 0.040 |
Why?
|
| Biomechanical Phenomena | 1 | 2019 | 476 | 0.040 |
Why?
|
| BRCA1 Protein | 1 | 2019 | 204 | 0.040 |
Why?
|
| Cell Proliferation | 2 | 2013 | 1652 | 0.030 |
Why?
|
| United States | 2 | 2021 | 6989 | 0.030 |
Why?
|
| Glasgow Coma Scale | 1 | 2015 | 73 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2017 | 784 | 0.030 |
Why?
|
| Ventilator Weaning | 1 | 2014 | 24 | 0.030 |
Why?
|
| Speech | 1 | 2014 | 85 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2015 | 487 | 0.030 |
Why?
|
| Drug Therapy | 1 | 2013 | 70 | 0.030 |
Why?
|
| Disease Management | 1 | 2015 | 329 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2015 | 860 | 0.030 |
Why?
|
| Watchful Waiting | 1 | 2013 | 63 | 0.030 |
Why?
|
| Child | 2 | 2015 | 7174 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2017 | 1719 | 0.030 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2013 | 127 | 0.030 |
Why?
|
| Carcinogenesis | 1 | 2014 | 211 | 0.030 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2013 | 181 | 0.030 |
Why?
|
| Antigens, Surface | 1 | 2012 | 103 | 0.030 |
Why?
|
| Capital Financing | 1 | 2011 | 4 | 0.030 |
Why?
|
| Fees, Medical | 1 | 2011 | 10 | 0.030 |
Why?
|
| Facility Design and Construction | 1 | 2011 | 5 | 0.030 |
Why?
|
| Group Practice | 1 | 2011 | 7 | 0.030 |
Why?
|
| Wisconsin | 1 | 2011 | 41 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2020 | 2624 | 0.020 |
Why?
|
| Incidence | 1 | 2016 | 1595 | 0.020 |
Why?
|
| Trauma Severity Indices | 1 | 2011 | 44 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2014 | 1534 | 0.020 |
Why?
|
| Length of Stay | 1 | 2014 | 736 | 0.020 |
Why?
|
| Intensive Care Units | 1 | 2014 | 396 | 0.020 |
Why?
|
| Logistic Models | 1 | 2014 | 1213 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2014 | 1109 | 0.020 |
Why?
|
| Veins | 1 | 2010 | 95 | 0.020 |
Why?
|
| Constriction, Pathologic | 1 | 2010 | 217 | 0.020 |
Why?
|
| Arteries | 1 | 2010 | 180 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2014 | 1265 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2015 | 2486 | 0.020 |
Why?
|
| Risk Factors | 1 | 2019 | 5499 | 0.020 |
Why?
|
| Infant | 1 | 2015 | 3160 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2015 | 3731 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2013 | 1431 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2010 | 1237 | 0.020 |
Why?
|
| Biomarkers, Tumor | 1 | 2014 | 1549 | 0.020 |
Why?
|
| Rats | 1 | 2010 | 4041 | 0.010 |
Why?
|